Amylyx Pharmaceuticals, Inc. (AMLX)
Company Info
ISIN | US03237H1014 |
---|---|
CUSIP | 03237H101 |
Sector | Healthcare |
Industry | Biotechnology |
Highlights
Market Cap | $1.22B |
---|---|
EPS | -$1.18 |
Revenue (TTM) | $191.87M |
Gross Profit (TTM) | -$74.21M |
EBITDA (TTM) | -$80.29M |
Year Range | $17.80 - $41.93 |
Target Price | $47.40 |
Short % | 17.71% |
Short Ratio | 8.02 |
Share Price Chart
Loading data...
Performance
The chart shows the growth of an initial investment of $10,000 in Amylyx Pharmaceuticals, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Compare to other instruments
Return
Amylyx Pharmaceuticals, Inc. had a return of -50.96% year-to-date (YTD) and -39.09% in the last 12 months.
Period | Return | Benchmark |
---|---|---|
1 month | -16.96% | -5.04% |
6 months | -36.73% | 4.21% |
Year-To-Date | -50.96% | 11.29% |
1 year | -39.09% | 16.17% |
5 years (annualized) | 0.16% | -4.78% |
10 years (annualized) | N/A | N/A |
Monthly Returns Heatmap
Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
2023 | -15.74% | -3.20% | -13.06% | -12.64% | 8.72% | -8.06% | -15.07% |
Risk-Adjusted Performance
This table presents a comparison of risk-adjusted performance metrics for Amylyx Pharmaceuticals, Inc. (AMLX) and S&P 500 (^GSPC). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Sharpe ratio | Sortino ratio | Omega ratio | Calmar ratio | Ulcer Index | |
---|---|---|---|---|---|
AMLX Amylyx Pharmaceuticals, Inc. | -0.78 | ||||
^GSPC S&P 500 | 1.04 |
Dividend History
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way.
Worst Drawdowns
The table below shows the maximum drawdowns of the Amylyx Pharmaceuticals, Inc.. A maximum drawdown is an indicator of risk. It shows a reduction in portfolio value from its maximum due to a series of losing trades.
The maximum drawdown since January 2010 for the Amylyx Pharmaceuticals, Inc. is 79.18%, recorded on May 11, 2022. It took 104 trading sessions for the portfolio to recover.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
---|---|---|---|---|---|---|
-79.18% | Mar 1, 2022 | 50 | May 11, 2022 | 104 | Oct 10, 2022 | 154 |
-55.83% | Jan 30, 2023 | 162 | Sep 21, 2023 | — | — | — |
-17.59% | Feb 2, 2022 | 8 | Feb 11, 2022 | 5 | Feb 18, 2022 | 13 |
-15.23% | Dec 2, 2022 | 12 | Dec 19, 2022 | 23 | Jan 24, 2023 | 35 |
-13.39% | Oct 27, 2022 | 8 | Nov 7, 2022 | 13 | Nov 25, 2022 | 21 |
Volatility Chart
The current Amylyx Pharmaceuticals, Inc. volatility is 10.41%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.